Phenotype, Genotype and Biomarkers 2

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, the investigator wants to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genotype refers to your genetic information). The investigator also wants to identify biomarkers of ALS and related diseases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Healthy Volunteers: t
View:

• Clinical diagnosis or suspicion of ALS or a related disorder, including, but not limited to, ALS-FTD, PLS, HSP, FTD, Multisystem Proteinopathy (MSP) and PMA.

• Subject is able and willing to comply with study procedures

• Family member of an enrolled affected primary participant

Locations
United States
Florida
University of Miami
RECRUITING
Miami
Kansas
University of Kansas Medical Center
RECRUITING
Kansas City
Pennsylvania
University of Pennsylvania
RECRUITING
Philadelphia
Other Locations
South Africa
University of Cape Town
RECRUITING
Cape Town
Contact Information
Primary
Michael Benatar, MD, PhD
projectcreate@miami.edu
1-844-837-1031
Time Frame
Start Date: 2021-01-08
Estimated Completion Date: 2028-08
Participants
Target number of participants: 300
Treatments
Primary participants
Patients that have or are suspected to have ALS or a related neurodegenerative disease
Secondary Participants
Family members of primary participants enrolled in the study
Sponsors
Collaborators: National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Leads: University of Miami

This content was sourced from clinicaltrials.gov